Chemomab Therapeutics Ltd. Operating Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2023: USD -23.70 M

Chemomab Therapeutics Ltd. Operating Cash Flow is USD -23.70 M for the Trailing 12 Months (TTM) ending December 31, 2023, a 16.37% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Chemomab Therapeutics Ltd. Operating Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2022 was USD -20.37 M, a 64.62% change year over year.
  • Chemomab Therapeutics Ltd. Operating Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2021 was USD -12.37 M, a 136.05% change year over year.
  • Chemomab Therapeutics Ltd. Operating Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2020 was USD -5.24 M.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities